KRRO
Korro Bio, Inc.Company Information
- Company Name
- Korro Bio, Inc.
- CIK
- CIK0001703647
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- KRRO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- KRRO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-10
- Last sale
- 2026-09-14
- Shares purchased (TTM)
- 1,865,882
- Shares sold (TTM)
- 167,565
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 14,012,864
- Shares outstanding
- 17,618,441
- Ownership
- 79.54%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 6.52%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 25 | 62 | 22 | 24 | 34 | 64 | 56 | 63 | 91 | 139 | 166 | 42 | ||||||
| Available For Sale Securities Debt Securities Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Marketable Securities Current | 90 | 52 | 53 | 68 | 63 | 51 | 70 | 74 | 66 | - | 0 | - | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 121 | 120 | 82 | 98 | 103 | 121 | 132 | 153 | 164 | 146 | 173 | 43 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Accounts And Other Receivables Net Current | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 10 | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 6 | 6 | 6 | 5 | 5 | 4 | 4 | 4 | 4 | 3 | 3 | 0 | ||||||
| Restricted Cash Current | - | - | 1 | - | - | 0 | 0 | 2 | 2 | 4 | 4 | - | ||||||
| Property Plant And Equipment Net | 7 | 8 | 8 | 24 | 25 | 27 | 28 | 29 | 25 | 21 | 16 | 1 | ||||||
| Operating Lease Right Of Use Asset | 8 | 8 | 8 | 23 | 24 | 24 | 24 | 24 | 25 | 26 | 27 | 1 | ||||||
| Restricted Cash Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 2 | ||||||
| Restricted Cash Equivalents Noncurrent | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | - | ||||||
| Marketable Securities Noncurrent | 23 | 43 | 10 | 10 | 23 | 24 | 37 | 32 | 30 | - | 0 | - | ||||||
| Other Assets Noncurrent | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 2 | 3 | - | ||||||
| Assets | 163 | 184 | 114 | 162 | 180 | 202 | 226 | 244 | 250 | 198 | 222 | 46 | ||||||
Liabilities | ||||||||||||||||||
| Accounts Payable Current | 4 | 2 | 2 | 2 | 5 | 4 | 4 | 6 | 6 | 5 | 7 | 0 | ||||||
| Accrued Liabilities Current | 5 | 10 | 8 | 6 | 6 | 4 | 6 | 5 | 6 | 5 | 10 | 8 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 13 | 15 | 12 | 15 | 17 | 13 | 15 | 14 | 12 | 11 | 19 | 10 | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 3 | 2 | 2 | 1 | 0 | 0 | 1 | 2 | 1 | ||||||
| Long Term Debt Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Deferred Revenue Current | 1 | 0 | 0 | 3 | 4 | 3 | 4 | 2 | - | - | 0 | - | ||||||
| Operating Lease Liability Noncurrent | 39 | 40 | 41 | 42 | 42 | 43 | 43 | 42 | 38 | 35 | 31 | 0 | ||||||
| Long Term Loans From Bank | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Deferred Revenue Noncurrent | 7 | 8 | 8 | 5 | 5 | 6 | 6 | 8 | - | - | 0 | - | ||||||
| Other Liabilities Noncurrent | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Liabilities | 60 | 64 | 62 | 63 | 65 | 63 | 66 | 64 | 52 | 47 | 52 | 10 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 526 | 523 | 435 | 433 | 431 | 429 | 427 | 424 | 422 | 354 | 353 | 340 | ||||||
| Stockholders Equity | 103 | 120 | 51 | 99 | 115 | 139 | 160 | 180 | 198 | 151 | 170 | -153 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | - | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -422 | -403 | -384 | -334 | -316 | -290 | -267 | -245 | -224 | -203 | -183 | -304 | ||||||
| Liabilities And Stockholders Equity | 163 | 184 | 114 | 162 | 180 | 202 | 226 | 244 | 250 | 198 | 222 | 46 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 15 | 14 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 37 | ||||||
| Shares Outstanding | 15 | 14 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 37 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKorro Bio, Inc. (KRRO) — SEC Financial Statements & Analysis
Korro Bio, Inc. (KRRO) is a pharmaceutical preparations company, incorporated in DE. Korro Bio, Inc. trades on Nasdaq as: KRRO. Korro Bio, Inc. (KRRO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Korro Bio, Inc. carries a market cap of $232.21M, a P/E ratio of -2.18x, a P/B ratio of 2.25x, a P/S ratio of 97.49x, an enterprise value of $207.31M, and an EV/EBITDA multiple of -1.93x. On profitability, it posts an operating margin of -4625.48%, a net margin of -4477.08%, a Return on Equity (ROE) of -97.69%, a Return on Assets (ROA) of -62.03%, and a Return on Invested Capital (ROIC) of -136.64%. Per share, it reports EPS of $-6.05, diluted EPS of $-6.05, free cash flow per share of $-3.87, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -62.08% year-over-year, net income growth of 16.74% year-over-year, and EPS growth of -37.78% year-over-year. On the balance sheet, it maintains a current ratio of 9.55x, a quick ratio of 9.11x, working capital of $108.00M, a debt-to-equity ratio of 0.58x, a debt ratio of 0.37, an interest coverage ratio of -447.49x, free cash flow of $-68.27M (TTM), and net debt of $-24.91M. Figures sourced from SEC EDGAR.
- Market Cap
- $232.21M
- P/E TTM
- -2.18x
- EPS TTM
- $-6.05
- P/B TTM
- 2.25x
- ROE TTM
- -97.69%
- ROA TTM
- -62.03%
- Debt To Equity
- 0.58x
- Free Cash Flow TTM
- $-68.27M
- Net Revenue TTM Growth 1Y
- -62.08%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Korro Bio, Inc. in?
Korro Bio, Inc. (KRRO) operates in the Pharmaceutical Preparations industry.
What exchange does KRRO trade on?
Korro Bio, Inc. (KRRO) trades on the Nasdaq.
Where is Korro Bio, Inc. incorporated?
Korro Bio, Inc. is incorporated in DE.
When was Korro Bio, Inc. (KRRO)'s most recent SEC filing?
Korro Bio, Inc. (KRRO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is KRRO's market cap?
Korro Bio, Inc. (KRRO) has a market capitalization of $232.21M as of 2026-06-30.
What is KRRO's EPS (earnings per share)?
Korro Bio, Inc. (KRRO)'s trailing twelve month EPS is $-6.05 as of 2026-06-30.
What is KRRO's ROE (return on equity)?
Korro Bio, Inc. (KRRO)'s trailing twelve month Return on Equity (ROE) is -97.69% as of 2026-06-30.
What is KRRO's ROA (return on assets)?
Korro Bio, Inc. (KRRO)'s trailing twelve month Return on Assets (ROA) is -62.03% as of 2026-06-30.
What is KRRO's ROIC (return on invested capital)?
Korro Bio, Inc. (KRRO)'s trailing twelve month Return on Invested Capital (ROIC) is -136.64% as of 2026-06-30.
What is KRRO's EV/EBITDA?
Korro Bio, Inc. (KRRO)'s trailing twelve month EV/EBITDA is -1.93x as of 2026-06-30.